This tool is for research exploration only. It is not a medical device and does not provide medical advice. Drug candidates, evidence scores, and AI-generated content are not clinical recommendations. Always consult your medical team before making any treatment decisions.

Drug Candidates

9 candidates mapped to SDH-deficient disease pathways

All (27)established (4)clinical trial (4)preclinical (13)theoretical (6)
Rogaratinib
clinical trial

Pan-FGFR inhibitor (FGFR1/2/3/4)

Fgfr SignalingEpigenetic Dysregulation
Evidence Score
76
Temozolomide

Temodar, Temodal

clinical trial

Alkylating agent

Epigenetic Dysregulation
Evidence Score
68
FDA Approved
Tazemetostat

Tazverik

clinical trial

EZH2 inhibitor (PRC2 inhibitor)

Epigenetic Dysregulation
Evidence Score
65
FDA Approved
Azacitidine

Vidaza

preclinical

DNA methyltransferase inhibitor (hypomethylating agent)

Epigenetic Dysregulation
Evidence Score
52
FDA Approved
Decitabine

Dacogen

preclinical

DNA methyltransferase inhibitor (hypomethylating agent)

Epigenetic Dysregulation
Evidence Score
50
FDA Approved
Ascorbic Acid (High-dose IV)
preclinical

TET enzyme cofactor / α-KG-dependent dioxygenase activator

Epigenetic DysregulationOxidative Stress Ros
Evidence Score
38
Birabresib

OTX015, MK-8628

theoretical

BET bromodomain inhibitor (pan-BRD2/3/4)

Epigenetic Dysregulation
Evidence Score
33
Panobinostat

Farydak

theoretical

Pan-HDAC inhibitor

Epigenetic Dysregulation
Evidence Score
30
FDA Approved
Enasidenib

Idhifa

theoretical

IDH2 inhibitor

Epigenetic Dysregulation
Evidence Score
28
FDA Approved